Holen Sie sich die Stockscreener-App
1.44
1.37%
-0.02
Handel nachbörslich:
1.40
-0.04
-2.78%
Schlusskurs vom Vortag:
$1.46
Offen:
$1.43
24-Stunden-Volumen:
565.07K
Relative Volume:
0.25
Marktkapitalisierung:
$88.18M
Einnahmen:
$5.03M
Nettoeinkommen (Verlust:
$-185.41M
KGV:
-0.466
EPS:
-3.09
Netto-Cashflow:
$-139.79M
1W Leistung:
+9.92%
1M Leistung:
-6.49%
6M Leistung:
-90.48%
1J Leistung:
-89.14%
1-Tages-Spanne:
$1.40
$1.4695
1-Wochen-Bereich:
$1.23
$1.4695
52-Wochen-Spanne:
$1.1001
$16.52
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Vergleichen Sie PLRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.44 | 88.18M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Pliant Therapeutics stock hits 52-week low at $1.2 amid sharp decline - Investing.com
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Major Breakthrough: Pliant Reveals Latest Bexotegrast Research Data in Three Key Presentations - Stock Titan
Pliant Therapeutics Announces Upcoming Presentations at the - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - ACCESS Newswire
Pliant Therapeutics: An Activist On Deck - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
PLRX stock touches 52-week low at $1.25 amid sharp annual decline - Investing.com Canada
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know - MSN
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics – PLRX - GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics – PLRX - menafn
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - GlobeNewswire Inc.
TANG CAPITAL MANAGEMENT LLC Acquires Significant Stake in Pliant Therapeutics Inc - GuruFocus
Pliant discontinues Phase 2b/3 trial of IPF treatment bexotegrast - Pulmonary Fibrosis News
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus.com
Pliant Therapeutics (NASDAQ:PLRX) Receives “Neutral” Rating from HC Wainwright - Defense World
Pliant Therapeutics Announces Interim Phase 1 Data for - GlobeNewswire
Pliant Therapeutics' Investigational Cancer Drug Shows Antitumor Activity Across Multiple Tumor Types - Benzinga
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors - Markets Insider
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial - Marketscreener.com
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’ - Yahoo Finance
Pliant Pops Poison Pill as Concentra Threat Looms - BioSpace
Pliant Therapeutics adopts shareholder rights plan By Investing.com - Investing.com Australia
Drug developers Pliant and Acelyrin adopt poison pill provisions to fend off activist investor - The Business Journals
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics - The Malaysian Reserve
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims o - GuruFocus
Pliant Therapeutics Signs Shareholder Rights Agreement -March 13, 2025 at 08:32 am EDT - Marketscreener.com
Pliant Therapeutics adopts shareholder rights plan - Investing.com India
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement - The Manila Times
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement to Protect Shareholder Interests - Nasdaq
Pliant Therapeutics Shields Against Hostile Takeover with Strategic Rights Plan - StockTitan
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims On Behalf Of Investors Of Pliant Therapeutics - MENAFN.COM
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF - MSN
Pliant Therapeutics (NASDAQ:PLRX) Cut to “Hold” at Leerink Partnrs - Defense World
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):